65797-52-6

Basic information

• Product Name: 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol
• Synonyms: 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol
• CAS NO: 65797-52-6
• Molecular Formula: C₁₂H₁₁F₆NO
• Molecular Weight: 299.2122592
• Mol File: 65797-52-6.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol(65797-52-6)
• EPA Substance Registry System: 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol(65797-52-6)

Safety Data

• Hazardous Substances Data: 65797-52-6(Hazardous Substances Data)

Usage

General Description

1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol, also known as A-803467, is a chemical compound with the molecular formula C15H20F6NO. It is a potent and selective blocker of the Nav1.8 voltage-gated sodium channel, which is involved in the transmission of pain signals in the nervous system. 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol has been extensively studied for its potential use as a therapeutic agent for the treatment of chronic pain conditions. Its unique structure and mechanism of action make it a promising candidate for the development of new analgesic drugs. Additionally, 1,1,1,3,3,3-Hexafluoro-2-(1,2,3,4-tetrahydro-quinolin-6-yl)-propan-2-ol has also been used as a research tool to study the role of the Nav1.8 channel in pain modulation and its potential as a target for pain management strategies.

Upstream product

• 635-46-1 1,2,3,4-tetrahydroisoquinoline 
• 684-16-2 Hexafluoroacetone 
• 920-66-1 1,1,1,3',3',3'-hexafluoro-propanol 
• 65797-60-6 2-(1-acetoacetyl-1,2,3,4-tetrahydro-quinolin-6-yl)-1,1,1,3,3,3-hexafluoro-propan-2-ol 
• 7440-44-0 pyrographite 

Relevant articles and documents

Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (RORγ/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity

We disclose the optimization of a high throughput screening hit to yield benzothiazine and tetrahydroquinoline sulfonamides as potent RORγt inverse agonists. However, a majority of these compounds showed potent activity against pregnane X receptor (PXR) and modest activity against liver X receptor α (LXRα). Structure-based drug design (SBDD) led to the identification of benzothiazine and tetrahydroquinoline sulfonamide analogs which completely dialed out LXRα activity and were less potent at PXR. Pharmacodynamic (PD) data for compound 35 in an IL-23 induced IL-17 mouse model is discussed along with the implications of a high Ymax in the PXR assay for long term preclinical pharmacokinetic (PK) studies.

Cobalt-Catalyzed Selective Functionalization of Aniline Derivatives with Hexafluoroisopropanol

A cobalt-catalyzed site-selective functionalization of aniline derivatives with hexafluoroisopropanol, which enables the synthesis of a wide array of fluoroalkylated anilines, a class of highly valuable building blocks for further preparation of fluorinated functional products, is reported. The developed transformation proceeds with operational simplicity, use of earth-abundant metal catalyst, broad substrate scope, good functional group tolerance, and mild reaction conditions.

ANILINO LIVER X-RECEPTOR MODULATORS

The present invention is directed to selective LXR modulators, small molecule compounds corresponding to Formula I and is further directed to a process of treating a condition in a mammal that is modulated by LXR using a therapeutically effective dose of a compound of Formula I.